Passage Bio, Inc.
PASGNASDAQHealthcare● Active
$5.47
$-0.15(-2.67%)
Market Cap$17546721
P/E Ratio—
52W High$20
52W Low$3.935
Passage Bio, Inc. (PASG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PASG · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$2.36
Est. -$2.15 · -9.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
PASG reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$2.44 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$2.15 | -$2.36 | -9.8% | — | — | — |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$2.19 | -$4.08 | -86.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$2.64 | -$2.44 | +7.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$4.00 | -$2.96 | +26.0% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$4.80 | -$5.00 | -4.2% | — | — | — |
| ▲ Q1 FY2025 | Mar 4, 2025 | -$0.21 | -$0.20 | +4.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.23 | -$0.31 | -34.8% | — | $0.00B | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$2.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$2.36
EPS Est.
-$2.15
EPS Surpr.
-9.8%
Revenue
—
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$4.08
EPS Est.
-$2.19
EPS Surpr.
-86.3%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$2.44
EPS Est.
-$2.64
EPS Surpr.
+7.6%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$2.96
EPS Est.
-$4.00
EPS Surpr.
+26.0%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$5.00
EPS Est.
-$4.80
EPS Surpr.
-4.2%
Revenue
—
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.21
EPS Surpr.
+4.8%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.31
EPS Est.
-$0.23
EPS Surpr.
-34.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-2.12 | $-2.12 | $-2.12 | 1 |
| Q3 FY2026 | $-2.63 | $-2.46 | $-2.28 | 3 |
| Q2 FY2026 | $-2.78 | $-2.44 | $-2.10 | 3 |
| Q1 FY2026 | $-3.65 | $-2.76 | $-1.86 | 3 |
| Q4 FY2025 | $-3.13 | $-2.57 | $-1.99 | 3 |
| Q3 FY2025 | $-3.27 | $-2.76 | $-2.24 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -9.8% | $4.40 | $5.03 | +14.32% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -86.3% | $8.78 | $8.00 | -8.88% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +7.6% | $6.29 | $6.71 | +6.68% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +26.0% | $5.90 | $5.61 | -4.92% |
| ▼ Q2 FY2025 | May 13, 2025 | -4.2% | $6.17 | $5.90 | -4.38% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +4.8% | $9.60 | $8.51 | -11.35% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -34.8% | $13.36 | $11.64 | -12.87% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +16.1% | $16.46 | $15.60 | -5.22% |
Q2 FY2026+14.32%
Report Date
May 12, 2026
EPS Beat/Miss
-9.8%
Price Before
$4.40
Price After
$5.03
Q1 FY2026-8.88%
Report Date
Mar 3, 2026
EPS Beat/Miss
-86.3%
Price Before
$8.78
Price After
$8.00
Q4 FY2025+6.68%
Report Date
Nov 10, 2025
EPS Beat/Miss
+7.6%
Price Before
$6.29
Price After
$6.71
Q3 FY2025-4.92%
Report Date
Aug 12, 2025
EPS Beat/Miss
+26.0%
Price Before
$5.90
Price After
$5.61
Q2 FY2025-4.38%
Report Date
May 13, 2025
EPS Beat/Miss
-4.2%
Price Before
$6.17
Price After
$5.90
Q1 FY2025-11.35%
Report Date
Mar 4, 2025
EPS Beat/Miss
+4.8%
Price Before
$9.60
Price After
$8.51
Q4 FY2024-12.87%
Report Date
Nov 13, 2024
EPS Beat/Miss
-34.8%
Price Before
$13.36
Price After
$11.64
Q3 FY2024-5.22%
Report Date
Aug 8, 2024
EPS Beat/Miss
+16.1%
Price Before
$16.46
Price After
$15.60
Avg Beat Reaction-3.70%
Avg Miss Reaction-2.95%
Beat Rate4 / 8 quarters
Largest Move+14.32% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PASG ends December
Passage Bio, Inc. (PASG) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-2.36 — missing the analyst consensus of $-2.15 by -9.8%. The next PASG earnings date is expected around September 1, 2026.
Each quarter, investors track PASG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PASG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PASG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PASG earnings · 5 questionsPassage Bio, Inc.'s next earnings report is expected around September 1, 2026. PASG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PASG historically reports after market close (AMC).
PASG earnings datewhen is PASG earningsPASG next earnings datewhen does PASG report earningsPASG earnings calendar
▸ Source: FMP · Passage Bio, Inc. SEC filings · US GAAP · Passage Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026